Maravai LifeSciences Holdings, Inc.
MRVI
$2.45
$0.062.51%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -21.40% | -13.21% | -11.68% | -34.94% | -49.51% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -21.40% | -13.21% | -11.68% | -34.94% | -49.51% |
| Cost of Revenue | 2.90% | -0.93% | 1.64% | -10.81% | -11.68% |
| Gross Profit | -50.09% | -28.83% | -25.81% | -50.88% | -66.48% |
| SG&A Expenses | 2.45% | 7.32% | 9.83% | 5.65% | 11.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.44% | 3.14% | 5.91% | -4.54% | -2.33% |
| Operating Income | -139.74% | -98.55% | -214.39% | -160.98% | -122.29% |
| Income Before Tax | -158.91% | -149.29% | -142.96% | 661.46% | 208.92% |
| Income Tax Expenses | -100.50% | -100.26% | -100.25% | 47,572.98% | 4,123.28% |
| Earnings from Continuing Operations | -107.69% | -83.91% | -90.46% | -653.96% | -195.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 371.60% | 349.32% | 502.19% | 390.59% | 132.45% |
| Net Income | -45.00% | -25.85% | -23.54% | -1,023.56% | -277.88% |
| EBIT | -139.74% | -98.55% | -214.39% | -160.98% | -122.29% |
| EBITDA | -3,346.10% | -1,020.56% | -277.69% | -102.43% | -100.75% |
| EPS Basic | -34.80% | -17.45% | -16.25% | -991.27% | -276.74% |
| Normalized Basic EPS | -85.20% | -87.13% | -87.72% | 80,713.64% | 1,964.59% |
| EPS Diluted | -34.71% | -17.38% | -16.16% | -996.29% | -276.97% |
| Normalized Diluted EPS | -85.20% | -87.13% | -87.72% | 80,713.64% | 1,965.97% |
| Average Basic Shares Outstanding | 7.29% | 6.51% | 4.52% | 2.79% | 1.04% |
| Average Diluted Shares Outstanding | 7.29% | 6.51% | 4.52% | 2.79% | 1.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |